ArticlePloS one2026
Metabolic resistance drives cross-resistance in Aedes albopictus to pyriproxyfen and pyrethroid insecticides.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aedes albopictus is a major global vector of arboviruses. Pyriproxyfen, an insect growth regulator, is increasingly used for mosquito control, but the potential for resistance and cross-resistance with pyrethroids poses a serious threat. Through 13 generations of laboratory selection, we established a highly pyriproxyfen-resistant Ae. albopictus strain (Lab-R, RR50 = 10.12). This strain developed moderate to high cross-resistance to the permethrin, deltamethrin, and beta-cypermethrin (RR50 = 8.11-10.30). Resistance was associated with significant fitness costs, including prolonged larval development, reduced female longevity, and lower fecundity and egg hatching. Crucially, resistance of Lab-R was driven by enhanced metabolic enzyme activity (P450s, GSTs, Car Es), with no target-site mutations detected in the CHS-1 or kdr genes. Synergist assays confirmed that enzyme inhibitors largely restored insecticide susceptibility. These findings demonstrate that metabolic resistance mediates cross-resistance between pyriproxyfen and pyrethroids in Ae. albopictus, carrying substantial fitness trade-offs. For vector control programs, this warns against the overreliance on rotational or sequential use of pyriproxyfen and pyrethroids as the sole rotation strategy, emphasizes the need for routine monitoring of metabolic resistance, and supports the potential use of synergists such as PBO to restore efficacy where resistance has emerged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.